Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor

A Belley1, K Chadee

  • 1Institute of Parasitology, McGill University, Quebec, Canada.

Gastroenterology
|December 2, 1999
PubMed
Abstract

Insights

Prostaglandin E(2) (PGE(2)) stimulates mucin secretion via the EP(4) receptor, increasing cyclic adenosine monophosphate (cAMP) levels. This pathway is crucial for innate host defense in the colon.

Area of Science:

  • Gastroenterology
  • Immunology
  • Cell Biology

Background:

  • Mucins are key components of the innate immune system in the intestines, protecting against pathogens and irritants.
  • The regulation of mucin secretion during inflammation is not well understood.
  • Prostaglandin E(2) (PGE(2)) is a significant mediator during intestinal inflammation.

Purpose of the Study:

  • To investigate the receptor-signaling pathway of prostaglandin E(2) (PGE(2)) in regulating mucin exocytosis.
  • To determine the role of specific prostaglandin E(2) receptors (EP) in colonic mucin secretion.
  • To elucidate the downstream signaling mechanisms, including cyclic adenosine monophosphate (cAMP), involved in PGE(2)-mediated mucin release.

Main Methods:

  • Identification of EP receptors using reverse-transcription polymerase chain reaction (RT-PCR) and [(3)H]PGE(2) binding assays.
  • Quantification of intracellular cyclic adenosine monophosphate ([cAMP](i)) via enzyme immunoassay.
  • Measurement of mucin secretion using metabolic labeling, column chromatography, immunoblot analysis, and density gradient centrifugation.

Main Results:

  • EP(2), EP(3), and EP(4) receptors were identified in colonic epithelial cells.
  • PGE(2) and specific EP receptor agonists (EP(4) and EP(3)/EP(4)) dose-dependently stimulated mucin secretion and [cAMP](i) production.
  • Inhibition of adenylate cyclase blocked the stimulatory effects, confirming the involvement of the cAMP pathway.
  • EP(4) receptor activation was confirmed to be linked to mucin exocytosis in vivo using rat colon models.

Conclusions:

  • Prostaglandin E(2) (PGE(2)) stimulates mucin exocytosis through coupling to the EP(4) receptor.
  • This process is dependent on the elevation of intracellular cyclic adenosine monophosphate (cAMP) levels.
  • The EP(4) receptor-cAMP pathway represents a significant mechanism for regulating mucin secretion in the colon.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...